QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 raymond-james-maintains-strong-buy-on-adma-biologics-raises-price-target-to-10

Raymond James analyst Elliot Wilbur maintains ADMA Biologics (NASDAQ:ADMA) with a Strong Buy and raises the price target fro...

 cantor-fitzgerald-maintains-overweight-on-adma-biologics-raises-price-target-to-10

Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...

 hc-wainwright--co-maintains-buy-on-adma-biologics-raises-price-target-to-10

HC Wainwright & Co. analyst Raghuram Selvaraju maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price ta...

 mizuho-maintains-buy-on-adma-biologics-raises-price-target-to-12

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $10 to $12.

 adma-biologics-q1-2024-gaap-eps-008-beats-005-estimate-sales-81875m-beat-77275m-estimate

ADMA Biologics (NASDAQ:ADMA) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $0.05 ...

 hc-wainwright--co-reiterates-buy-on-adma-biologics-raises-price-target-to-75

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price t...

 adma-biologics-reports-fda-approvals-of-extended-room-temperature-storage-conditions-for-asceniv--bivigam

The room temperature approval applies to all existing ASCENIV and BIVIGAM lots currently in the commercial supply chain as well...

 piper-sandler-maintains-buy-on-adma-biologics-raises-price-target-to-10

Piper Sandler analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and raises the price target from $9 ...

 cantor-fitzgerald-maintains-overweight-on-adma-biologics-raises-price-target-to-8

Cantor Fitzgerald analyst Kristen Kluska maintains ADMA Biologics (NASDAQ:ADMA) with a Overweight and raises the price targe...

 hc-wainwright--co-reiterates-buy-on-adma-biologics-maintains-6-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ADMA Biologics (NASDAQ:ADMA) with a Buy and maintains $6 price...

 recap-adma-biologics-q4-earnings
Recap: ADMA Biologics Q4 Earnings
02/28/2024 21:30:30

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION